Real-World Data as Real Evidence Showing Real-World Outcomes
Main Article Content
Keywords
Real world Data, Evidence, Outcomes
Abstract
N/A
References
1. US Food and Drug Administration. Framework for FDAs Real World Evidence Program Dec 2018. Available at: https://www.fda.gov/media/120060/download
2. Ostrowski M, Jo Y., Gebrael G., Chehade CH, Ozay ZI, et al. First-line ipilimumab with nivolumab versus immune checkpoint inhibitors with tyrosine kinase inhibitors in patients with intermediate-or poor-risk metastatic clear cell renal cell carcinoma. J Kidney Cancer. 2025;12(2): 27–36. 10.15586/jkc.v12i2.387
2. Ostrowski M, Jo Y., Gebrael G., Chehade CH, Ozay ZI, et al. First-line ipilimumab with nivolumab versus immune checkpoint inhibitors with tyrosine kinase inhibitors in patients with intermediate-or poor-risk metastatic clear cell renal cell carcinoma. J Kidney Cancer. 2025;12(2): 27–36. 10.15586/jkc.v12i2.387
Article Sidebar
Published
May 14, 2025
Article Details
How to Cite
Real-World Data as Real Evidence Showing Real-World Outcomes. (2025). Journal of Kidney Cancer, 12(2), 46-47. https://doi.org/10.15586/jkcvhl.v12i2.404
Section
Editorial
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
Real-World Data as Real Evidence Showing Real-World Outcomes. (2025). Journal of Kidney Cancer, 12(2), 46-47. https://doi.org/10.15586/jkcvhl.v12i2.404